By Kim Richters

Bayer AG over the weekend presented two new studies and results for its blood thinner Xarelto.

The German pharmaceutical and chemical company said the drug plus aspirin reduces the combined risk of limb ischemia and major cardiovascular events for patients who have a symptomatic peripheral artery disease after revascularization.

The results are from the Phase 3 VOYAGER PAD study, the company said.

Another study showed that Xarelto lowers the risk of major venous thromboembolism after minor orthopaedic surgery, Bayer said.

This data is from the from the clinical Phase 3 trial PRONOMOS, it said.

Write to Kim Richters at kim.richters@wsj.com

(END) Dow Jones Newswires

March 30, 2020 02:39 ET (06:39 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Bayer Charts.
Bayer (TG:BAYN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Bayer Charts.